Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Biogen Inc 225 BINNEY STREET CAMBRIDGE MA 02142 USA

www.biogen.com Employees: 7,570 P: 617-679-2000

Description:

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).

Key Statistics

Overview:

Market Capitalization, $K 21,343,460
Enterprise Value, $K 27,081,760
Shares Outstanding, K 145,719
Annual Sales, $ 9,836 M
Annual Net Income, $ 1,161 M
Last Quarter Sales, $ 2,466 M
Last Quarter Net Income, $ 388,500 K
EBIT, $ 2,539 M
EBITDA, $ 3,066 M
60-Month Beta -0.08
% of Insider Shareholders 0.16%
% of Institutional Shareholders 87.93%
Float, K 145,486
% Float 99.84%
Short Volume Ratio 0.35

Growth:

1-Year Return -40.98%
3-Year Return -37.78%
5-Year Return -51.19%
5-Year Revenue Growth -26.89%
5-Year Earnings Growth -43.82%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 4.08 on 10/30/24
Next Earnings Date 02/11/25
Earnings Per Share ttm 15.98
EPS Growth vs. Prev Qtr -22.73%
EPS Growth vs. Prev Year -6.42%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 900-829 on 02/01/17

BIIB Ratios

Ratio
Price/Earnings ttm 9.22
Price/Earnings forward 8.97
Price/Earnings to Growth 1.71
Return-on-Equity % 14.98%
Return-on-Assets % 8.59%
Profit Margin % 11.81%
Debt/Equity 0.28
Price/Sales 2.18
Price/Cash Flow 8.00
Price/Book 1.31
Book Value/Share 112.26
Interest Coverage -1.43
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar